EpCAM has been reported to be responsible for persistence of minimal residual disease and latent relapse of prostate cancer, presumably by affecting the susceptibility to the EGF ligand and regulating the AMPK signaling pathway [39]. Here, EGF is linked to prostate carcinoma.